'Mda mb 231' diaporamas de présentation

Er resistent over for " programmeret celledød ". Kan danne metastaser. En kræftcelles egenskaber (udvalg):. Normal celle. Kræftcelle. Deler sig ukontrolleret. Gen-forandringer. Tumordannelse – ophobning af forandringer i cellens gener. Spirende kræftceller. Fuldmodne kræftceller.

T47D. Hs 578t. EpCAM high. EpCAM low. MCF-7. MDA-MB-231. EMT. shRNA ns-crtl. Cytokeratin high. shRNA EpCAM. Vimentin high. Control. EpCAM. EpCAM. crtl. crtl. shRNA. T. T. CAM. CAM. T. T. T. CAM. CAM. CAM. CAM. T. CAM. • proangiogenic • invasive.

Supplementary Figure S2. Rapamycin induction of p-AKT occurs within 1 hour and is not due to increased levels of p- Src. A. BT474. MCF7. MDA-MB-231. p-AKT. t-AKT. p- Src. t- Src. p-S6. t-S6. β -act. B. MCF7. BT474. MDA-MB-231. p-AKT. t -AKT. p- Src. t- Src.

Supplementary Figure 2. MDA-MB-231. MDA-MB-231 HM.

S. 7. A. No. Hy. MDA-MB-231. A549. B. No. No. Hy. Hy. HIF-1 a. b - actin. -. +. -. +. -. +. -. +. Gö6976 (3.5 µM). 3x k B-luc Fold induction (RLU). +. -. -. -. +. -. PU-H71. +. -. +. -. -. +. PKD2-wt.

Supplementary Figure 3. MDA-MB-231. MDA-MB-231 HM.

S.3. A. B. A549. MDA-MB-231. HCT-116. AKT1. HCT-116. A549. MDA-MB-231. RAF1. b - actin. -. +. -. +. -. +. PU-H71. b - actin. -. +. -. +. -. +. PU-H71. C. D. A549. MDA-MB-231. A549. MDA-MB-231. HCT-116. HCT-116. AKT1. RAF1. PARP. PARP. clv. PARP. clv. PARP.

Fig. 2. A. B. 20. 30. BT-474. cells/well. MCF-7. 25. 15. . . 20. 4. . 10. 10. . 15. 10. 5. siRNA1. C. OF. siGFP. siRNA2. siRNA3. 5. 0. 0. G0/G1. G0/G1. 80. S. S. G2/M. G2/M. BT-474. MCF-7. 60. 60. 40. 40. %. %. 20. 20. 0. siRNA1. siRNA1.

Supplementary Figure S1. (a). MDA-MB-468. +*. +*. MDA-MB-134. MDA-MB-435. MDA-MB-436. MDA-MB-157. HCC-1187. MDA-MB-361. MDA-MB-415. UACC-893. SUM-225. EFM-19. HCC-1569. HCC-1419. HCC-1395. ZR-75-1. UACC-732. HCC-1954. BT-474. CAMA-1. Hs 578T. BT-549. HCC-38. SK-BR-3.

Towards a fast, efficient assay for isolating circulating tumor cells. July 30, 2009. PI: Professor David Eddington Grad Student: Cari Launiere Me: Joey Labuz. Introduction. Breast, colon, prostate, and lung cancers accounted for nearly half of cancer deaths (American Cancer Society, 2008)

Austin Ramos Biomedical Engineering, URI BME 281. Nanodiamond Drug Delivery. Nanodiamonds. Nanoparticles that are less than 100 nm in diameter (1) Nanodiamonds are useful Biocompatibility Functional versatility Unique surface electrostatics Drug delivery Bypassing chemoresistance

Figure S1. RNA-seq results for caveolin-1 (Cav1). Upper panel: UCSC genome browser view. Lower panel: quantification o f Cav1 expression based on RNA-seq reads. See methods for details. **.